What question did this study set out to answer?

The study aims to assess the impact of crizanlizumab on vaso-occlusive crisis incidence in sickle cell disease patients compared to hydroxyurea.

December 8, 2025Blood

Increased risk of vaso-occlusive crisis in patients with sickle cell disease treated with crizanlizumab: A real-world analysis using the trinetx database

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort analysis shows crizanlizumab increased vaso-occlusive crisis risk compared to hydroxyurea in sickle cell disease.

The study aims to assess the impact of crizanlizumab on vaso-occlusive crisis incidence in sickle cell disease patients compared to hydroxyurea.
Retrospective cohort study using TriNetX electronic health records database
Inclusion of adults aged ≥18 years with HbSS genotype and documented vaso-occlusive crises
Patients categorized into crizanlizumab and hydroxyurea treatment cohorts
Propensity score matching performed to balance key confounders
Primary outcome was the rate of vaso-occlusive crises at 3 months, 1 year, and 3 years.
202 patients included after matching, 101 in each treatment cohort
Patients treated with crizanlizumab had a mean HbS of 45.9% and HbF of 4.9%
Crizanlizumab linked to higher risk of vaso-occlusive crises at 3 months (RR 1.37), 1 year (RR 1.36), and 3 years (RR 1.12)
Hospitalization rates did not differ significantly between the groups.

Jabiri et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark